AbbVie accused of delay tactics in $1.3bn Humira dispute

16-11-2023

Muireann Bolger

AbbVie accused of delay tactics in $1.3bn Humira dispute

Piotr Swat / Shutterstock.com

Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time.


AbbVie, Humira, Feud, Pharmaceutical  Accountability Foundation, Dutch healthcare system, patents, generics, overpricing, pharmaceutical dispute, drug

LSIPR